Luminex Reports First Quarter 2016 Results

AUSTIN, Texas, May 2, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2016.  Financial and operating highlights for the first quarter 2016 include the following:

• Consolidated first quarter revenue of $63.0 million, a 9 percent increase compared to the first quarter of 2015, including record assay and royalty revenues; and system revenue that grew 39 percent over the first quarter of 2015.
• Consolidated gross profit margin was 71% for the first quarter.
• Expanded first quarter 2016 operating margins to 19% from 17% in the first quarter 2015, as a result of both increased revenues and continued focus on controlling expenses.
• GAAP net income for the first quarter of 2016 was $8.8 million, or $0.21 per diluted share. Non-GAAP net income for the first quarter 2016 was $12.2 million, or $0.29 per diluted share (see Non-GAAP reconciliation).

"We've started 2016 very strongly, achieving record revenue, including the highest ever quarterly assay sales, healthy gross margins and overall profitability that grew 18% over last year. We attribute this positive momentum to the overall strength of the company's diversified business model, with an especially strong contribution from our life science partners," said Homi Shamir, President and Chief Executive Officer of Luminex. "Moving forward, we are building on a successful market introduction of ARIES^®; and our assay pipeline, which includes our next-generation ARIES^® chemistry, is proceeding according to plan. 2016 has started off well and we look forward to continuing another year of solid execution and growth."

Additional Highlights:

• Infectious disease assay sales were approximately 72 percent of total assay sales for the first quarter and genetic testing assays were 28 percent.
• 255 multiplexing analyzers were shipped during the quarter, included in this figure is a combination of MAGPIX^® systems, LX systems, and FLEXMAP 3D^® systems.

FINANCIAL OUTLOOK AND GUIDANCE

The Company raises the lower end of its 2016 annual revenue guidance by $2 million, resulting in a revised range of between $247 million and $255 million. The Company currently anticipates second quarter 2016 revenue to be between $60 million and $62 million.

CONFERENCE CALL

Management will host a conference call at 3:30 p.m. CDT/4:30 p.m. EDT, Monday, May 2, 2016 to discuss the operating highlights and financial results for the first quarter ended March 31, 2016. The conference call will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the 'replay' link.

Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP^® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base of multiplexing systems; the development progress of our pipeline products, including ARIES^® and NxTAG^® products, market acceptance of our products, including instruments, consumables and assays, regulatory clearance of our products; the ability of our investment in current initiatives and new products to drive long-term value for our shareholders; and, projected 2016 performance, including revenue guidance. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex' products and technology in development, including ARIES^® and NxTAG products, the uncertainty relating to increased focus on direct sales to the end user, dependence on strategic partners for development, commercialization and distribution of products, concentration of Luminex' revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex' technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges, the timing of and process for regulatory approvals, the impact of the ongoing uncertainty in global finance markets and changes in governmental funding, including its effects on the capital spending policies of Luminex' partners and end users and their ability to finance purchases of Luminex' products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, fluctuations in bulk purchases of consumables, fluctuations in product mix, and the seasonal nature of some of Luminex' assay products, Luminex' ability to obtain and enforce intellectual property protections on Luminex' products and technologies, risks and uncertainties associated with implementing Luminex' acquisition strategy, including Luminex' ability to obtain financing, Luminex' ability to integrate acquired companies or selected assets into Luminex' consolidated business operations, and the ability to recognize the benefits of Luminex' acquisitions, reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products, Luminex' ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, changes in principal members of Luminex' management staff, potential shortages, or increases in costs, of components or other disruptions to Luminex' manufacturing operations, competition and competitive technologies utilized by Luminex' competitors, Luminex' ability to successfully launch new products in a timely manner, Luminex' increasing dependency on information technology to enable Luminex to improve the effectiveness of Luminex' operations and to monitor financial accuracy and efficiency, the implementation, including any modification, of Luminex' strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex, and risks relating to Luminex' foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; the burden of monitoring and complying with foreign and international laws and treaties; and the burden of complying with and change in international taxation policies, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.

To read full press release, please click here.